Company news
Minerva Neurosciences, Inc (NASDAQ:NERV) news
Minerva Neurosciences, Inc news releases on 6ix. Latest, Aug 28, 2026: Minerva Neurosciences to Participate in Two Upcoming Investor Conferences
Press releases & updates
Minerva Neurosciences to Participate in Two Upcoming Investor Conferences
August 28, 2026
Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates
August 7, 2026
Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs
June 1, 2026
Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference
May 18, 2026
Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates
May 5, 2026
Minerva Announces Leadership Transition
April 1, 2026
Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
March 30, 2026
Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026
March 25, 2026
Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum
March 12, 2026
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates
March 10, 2026
Minerva Neurosciences to Participate in The Citizens Life Sciences Conference
March 3, 2026
Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026
January 26, 2026
Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors
November 19, 2025
Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates
November 5, 2025
Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia through a Phase 3 Confirmatory Trial
October 22, 2025
Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved
October 21, 2025
Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Prepara...
October 20, 2025
Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results
August 14, 2025
Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates
May 13, 2025
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates
February 25, 2025
Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates
November 4, 2024
Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates
August 5, 2024
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates
April 30, 2024
Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
February 26, 2024
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates
February 21, 2024
Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates
November 6, 2023
Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates
July 31, 2023
Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market
June 27, 2023
Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates
May 14, 2023
Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
May 9, 2023
Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023
May 7, 2023
Minerva Neurosciences Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
April 30, 2023
Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business Updates
March 7, 2023
Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023
February 28, 2023
Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business Updates
November 8, 2022
Minerva Neurosciences to Report Third Quarter 2022 Financial Results and Business Updates on November 9, 2022
November 1, 2022
Minerva Neurosciences Receives Refusal to File Letter from FDA for its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
October 16, 2022
Minerva Neurosciences Announces Listing Transfer to Nasdaq Capital Market
September 8, 2022
Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
August 21, 2022
Minerva Neurosciences Reports Second Quarter 2022 Financial Results and Business Updates
August 8, 2022
Minerva Neurosciences Reports First Quarter 2022 Financial Results and Business Updates
May 3, 2022
Minerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of a New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
April 6, 2022
Minerva Neurosciences Reports Fourth Quarter 2021 Financial Results and Business Updates
February 28, 2022
Minerva Neurosciences Announces Publication of Roluperidone Phase 3 Study Results in Schizophrenia Bulletin
February 27, 2022
Minerva Neurosciences Reports Third Quarter 2021 Financial Results and Business Updates
November 7, 2021
Minerva Neurosciences Announces FDA Recommendation for Type C Meeting to Discuss Evidence for Use of Roluperidone as Monotherapy for the Treatment of Negative Symptoms in Patients with Schizophrenia in Advance of Potential NDA Submission
November 2, 2021
Minerva Neurosciences to Report Third Quarter 2021 Financial Results and Business Updates on November 8
October 31, 2021
Minerva Neurosciences Announces Promotion of Geoff Race to President
October 10, 2021
Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia
September 29, 2021
Minerva Neurosciences Announces Appointment of Dr. Ramana Kuchibhatla as Senior Vice President and Head of Research & Development
September 7, 2021